Arrowhead Pharmaceuticals Total Assets 2006-2019 | ARWR

Arrowhead Pharmaceuticals total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Arrowhead Pharmaceuticals total assets for the quarter ending September 30, 2019 were $0.350B, a 213.45% increase year-over-year.
  • Arrowhead Pharmaceuticals total assets for 2019 were $0.35B, a 213.45% increase from 2018.
  • Arrowhead Pharmaceuticals total assets for 2018 were $0.112B, a 7.29% increase from 2017.
  • Arrowhead Pharmaceuticals total assets for 2017 were $0.104B, a 18.85% decline from 2016.
Arrowhead Pharmaceuticals Annual Total Assets
(Millions of US $)
2019 $350
2018 $112
2017 $104
2016 $128
2015 $132
2014 $183
2013 $37
2012 $17
2011 $16
2010 $12
2009 $8
2008 $17
2007 $30
2006 $35
2005 $29
Arrowhead Pharmaceuticals Quarterly Total Assets
(Millions of US $)
Q4 2019 $350
Q3 2019 $337
Q2 2019 $334
Q1 2018 $341
Q4 2018 $112
Q3 2018 $113
Q2 2018 $127
Q1 2017 $88
Q4 2017 $104
Q3 2017 $115
Q2 2017 $127
Q1 2016 $144
Q4 2016 $128
Q3 2016 $86
Q2 2016 $95
Q1 2015 $111
Q4 2015 $132
Q3 2015 $145
Q2 2015 $162
Q1 2014 $162
Q4 2014 $183
Q3 2014 $197
Q2 2014 $203
Q1 2013 $93
Q4 2013 $37
Q3 2013 $41
Q2 2013 $12
Q1 2012 $15
Q4 2012 $17
Q3 2012 $16
Q2 2012 $20
Q1 2011 $23
Q4 2011 $16
Q3 2011 $13
Q2 2011 $15
Q1 2010 $15
Q4 2010 $12
Q3 2010 $15
Q2 2010 $8
Q1 2009 $9
Q4 2009 $8
Q3 2009 $8
Q2 2009 $10
Q1 2008 $15
Q4 2008 $17
Q3 2008 $19
Q2 2008 $25
Q1 2007 $31
Q4 2007 $30
Q3 2007 $37
Q2 2007 $27
Q1 2006 $34
Q4 2006 $35
Q3 2006 $41
Q2 2006 $45
Q1 2005 $26
Q4 2005 $29
Q3 2005 $31
Q2 2005 $15
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $5.400B $0.169B
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.758B 39.93
Takeda Pharmaceutical (TAK) Japan $62.374B 9.86
Astellas Pharma (ALPMY) Japan $32.724B 16.34
Eisai (ESALY) Japan $21.612B 41.66
Merck (MKGAF) Germany $16.401B 22.38
Grifols, S.A (GRFS) Spain $16.254B 21.30
Neurocrine Biosciences (NBIX) United States $9.639B 455.09
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.907B 36.24
Jazz Pharmaceuticals (JAZZ) Ireland $8.545B 10.91
Ionis Pharmaceuticals (IONS) United States $8.458B 17.13
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
IPSEN SA ADR (IPSEY) France $7.617B 0.00
STADA ARZNEIMI (STDAF) Germany $6.004B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.990B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
Hypermarcas (HYPMY) Brazil $5.646B 17.17
Evotec AG (EVTCY) Germany $4.191B 67.73
United Therapeutics (UTHR) United States $4.087B 0.00
Sage Therapeutics (SAGE) United States $3.959B 0.00
Nektar Therapeutics (NKTR) United States $3.955B 0.00
FibroGen (FGEN) United States $3.870B 113.72
PTC Therapeutics (PTCT) United States $3.316B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.273B 12.05
ChemoCentryx (CCXI) United States $2.534B 0.00
Zogenix (ZGNX) United States $2.433B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.150B 0.00
Xencor (XNCR) United States $2.130B 64.74
Tilray (TLRY) Canada $2.108B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.976B 63.00
Heron Therapeutics (HRTX) United States $1.941B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.829B 54.10
USANA Health Sciences (USNA) United States $1.760B 18.78
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.525B 10.41
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
Corcept Therapeutics (CORT) United States $1.474B 17.92
Theravance Biopharma (TBPH) Cayman Islands $1.432B 0.00
Endo (ENDP) Ireland $1.370B 2.52
Enanta Pharmaceuticals (ENTA) United States $1.143B 26.10
Portola Pharmaceuticals (PTLA) United States $1.118B 0.00
Karyopharm Therapeutics (KPTI) United States $1.070B 0.00
Aerie Pharmaceuticals (AERI) United States $1.053B 0.00
Dermira (DERM) United States $1.044B 0.00
Akebia Therapeutics (AKBA) United States $0.955B 0.00
Radius Health (RDUS) United States $0.907B 0.00
Collegium Pharmaceutical (COLL) United States $0.785B 0.00
ImmunoGen (IMGN) United States $0.683B 0.00
Flexion Therapeutics (FLXN) United States $0.668B 0.00
TherapeuticsMD (TXMD) United States $0.626B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.576B 0.00
Molecular Templates (MTEM) United States $0.507B 0.00
Organogenesis Holdings (ORGO) United States $0.501B 0.00
DURECT (DRRX) United States $0.483B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.483B 0.00
Translate Bio (TBIO) United States $0.483B 0.00
Ardelyx (ARDX) United States $0.470B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.453B 0.00
Innate Pharma SA (IPHYF) France $0.438B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.429B 52.00
Siga Technologies (SIGA) United States $0.422B 9.63
BioSpecifics Technologies Corp (BSTC) United States $0.419B 18.08
Aptorum Group (APM) Hong Kong, SAR China $0.418B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.412B 0.00
Calithera Biosciences (CALA) United States $0.398B 0.00
Lannett Co Inc (LCI) United States $0.393B 4.58
Spectrum Pharmaceuticals (SPPI) United States $0.366B 0.00
Recro Pharma (REPH) United States $0.366B 0.00
Harpoon Therapeutics (HARP) United States $0.357B 0.00
OptiNose (OPTN) United States $0.356B 0.00
Indivior (INVVY) United States $0.335B 1.21
KalVista Pharmaceuticals (KALV) United States $0.331B 0.00
Rafael Holdings (RFL) United States $0.325B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.289B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.286B 0.00
MEI Pharma (MEIP) United States $0.256B 0.00
Concert Pharmaceuticals (CNCE) United States $0.248B 0.00
Concordia (CXRXF) Canada $0.248B 0.00
Jounce Therapeutics (JNCE) United States $0.241B 3.22
Ocular Therapeutix (OCUL) United States $0.223B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.210B 0.00
IMV INC (IMV) Canada $0.203B 0.00
Nature's Sunshine Products (NATR) United States $0.188B 32.43
Taiwan Liposome (TLC) Taiwan $0.170B 0.00
Xeris Pharmaceuticals (XERS) United States $0.167B 0.00
CannTrust Holdings (CTST) Canada $0.167B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.151B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.146B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Redhill Biopharma (RDHL) Israel $0.134B 0.00
CV Sciences (CVSI) United States $0.125B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.114B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.114B 0.00
Otonomy (OTIC) United States $0.110B 0.00
PolarityTE (PTE) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.100B 0.00
Champions Oncology (CSBR) United States $0.098B 0.00
MediWound (MDWD) Israel $0.082B 0.00
CTI BioPharma (CTIC) United States $0.080B 0.00
Neos Therapeutics (NEOS) United States $0.080B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.077B 23.18
Aclaris Therapeutics (ACRS) United States $0.076B 0.00
Infinity Pharmaceuticals (INFI) United States $0.067B 0.00
Natural Alternatives (NAII) United States $0.066B 16.52
Entasis Therapeutics Holdings (ETTX) United States $0.064B 0.00
Nivalis Therapeutics (ALPN) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.062B 0.00
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
Onconova Therapeutics (ONTX) United States $0.057B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.050B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.048B 0.00
Iterum Therapeutics (ITRM) Ireland $0.046B 0.00
Jaguar Animal Health (JAGX) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Biomerica (BMRA) United States $0.029B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.028B 0.00
Regulus Therapeutics (RGLS) United States $0.025B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.019B 0.00
VAXART, INC (VXRT) United States $0.018B 0.00
Shineco (TYHT) China $0.018B 0.00
Novan (NOVN) United States $0.017B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.016B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Lipocine (LPCN) United States $0.013B 0.00
Flex Pharma (SLRX) United States $0.013B 0.00
Vical (BBI) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.012B 0.00
HANCOCK JAFFE (HJLI) United States $0.011B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.003B 0.00